Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain.

MLA

Muñoz, Andrés J., et al. “Cost-Effectiveness of Apixaban and Rivaroxaban in Thromboprophylaxis of Cancer Patients Treated with Chemotherapy in Spain.” Journal of Medical Economics, vol. 26, no. 1, Jan. 2023, pp. 1145–54. EBSCOhost, https://doi.org/10.1080/13696998.2023.2248839.

APA

Muñoz, A. J., Ortega, L., Gutiérrez, A., Gallardo, E., Rubio-Rodríguez, D., Rubio-Terrés, C., Morón, B., García-Alfonso, P., & Soria, J. M. (2023). Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain. Journal of Medical Economics, 26(1), 1145–1154. https://doi.org/10.1080/13696998.2023.2248839

Chicago

Muñoz, Andrés J., Laura Ortega, Ana Gutiérrez, Enrique Gallardo, Darío Rubio-Rodríguez, Carlos Rubio-Terrés, Blanca Morón, Pilar García-Alfonso, and José Manuel Soria. 2023. “Cost-Effectiveness of Apixaban and Rivaroxaban in Thromboprophylaxis of Cancer Patients Treated with Chemotherapy in Spain.” Journal of Medical Economics 26 (1): 1145–54. doi:10.1080/13696998.2023.2248839.